XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue $ 40,134 $ 15,735 $ 120,614 $ 106,367  
Constrained for Future Recognition [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue 2,300   1,100    
Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue 29,390 $ 17,359 77,439 $ 59,495  
AstraZeneca Agreements [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue 177,576   177,576   $ 175,646
AstraZeneca Agreements [Member] | China [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue 28,000   28,000    
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member]          
Contract with Customer, Liability [Abstract]          
Reductions to gross accounts receivable $ 2,500   $ 2,500   $ 500